Revised: 3/30/2023

Peri-transplant Immunosuppression Strategy – Joquetta Pass, 11503524

Donor Acceptance Considerations:

Marginal donors – older, minimal luminal coronary disease

OCS transport to increase radius

I. Pre-transplant

Densensitization protocol: CFZ/Bela/Plasmapheresis

1.5 volume plasmapheresis on Mondays and Wednesdays indefinitely

--> Transplant cardiology to ensure vasopressin for MAP > 60-65 and SBP > 90

*CFZ can cause mild AKI – usually reversible but requires careful management of fluids and hemodynamics

II. Once a heart is accepted, prior to transport to operating room

Urgent 1.5 volume plasmapheresis – intra-operative pheresis is historically not an option due to pheresis staff availability; However, the pheresis team is working with us to ensure pre- and post- transplant pheresis in the CICU and 5E. Please contact the pheresis resident and Dr. Jeanne Hendrickson as soon as a heart is accepted.

III. In the operating room

Thirty minutes prior to cross-clamp removal: Thymoglobulin induction at 1.5mg/kg

Revised: 3/30/2023

IV. Post-operatively

a) POD 0

- i. Cellcept 1500mg IV bid
- ii. Conservative Steroid Taper
- Plasmapheresis: Decision on POD # 0 pheresis vs. POD #1 based on stat prospective cross-match at the time of transplant – consider 1.5 volume plasma exchange if DSA crossed
- iv. Continue with <u>ATG Induction protocol</u> addenda to the ATG Induction Protocols
 a. MUST monitor daily Absolute CD3 (Monday Friday)
 - *b.* Decision for Follow-up ATG doses *only IF Absolute CD3 > 25.* ATG should be *continued until Absolute CD3 < 25.*
- v. Transplant cardiologist on call should call HLA team for expedite prospective crossmatch

b) POD 1

- i. Belatacept 10mg/kg
- Plasmapheresis: Decision on POD # 0 pheresis vs. POD #1 based on stat prospective cross-match at the time of transplant – consider 1.5 volume plasma exchange if DSA crossed
- c) Prograf:
 - i. Initiation: POD 1 or POD 3 based on degree of immunosuppression, as suggested by Absolute CD3 count
 - ii. Target: Prograf level 10-12

3 of 3

- d) Alterations in Immunosuppresion
 - i. Add: Belatacept 10mg/kg POD 7, 14, 21, 28 if ImmuKnow in the highest tertile or any evidence of early rejection (ACR/AMR/perioperative graft dysfunction)
 - ii. Reduction or cessation of immunosuppression pending leukopenia, thrombocytopenia, infectious complications, etc. with parameters similar to <u>ATG Induction Protocol</u>
- e) 3 months post-transplant
 - i. Restart Belatacept as maintenance immunosuppression
 - ii. Prograf Target: Should remain 8-12 for the first 6 months post transplant

Labs, Monitoring, Prophylaxis:

- a) Per ATG Induction Protocol
- b) Consider transplant infectious disease consult by POD #1
- c) Send ImmuKnow POD 7 and POD 14